Brexit, science and innovation: Government Response to the Committee’s Second Report: Fifth Special Report of Session 2017–19 by unknown
House of Commons





to the Committee’s 
Second Report
Fifth Special Report of Session 
2017–19
Ordered by the House of Commons 
to be printed 1 May 2018
HC 1008
Published on 4 May 2018
by authority of the House of Commons
Science and Technology Committee
The Science and Technology Committee is appointed by the House of Commons to 
examine the expenditure, administration and policy of the Government Office for 
Science and associated public bodies.
Current membership
Norman Lamb MP (Liberal Democrat, North Norfolk) (Chair)
Vicky Ford MP (Conservative, Chelmsford)
Bill Grant MP (Conservative, Ayr, Carrick and Cumnock)
Darren Jones MP (Labour, Bristol North West)
Liz Kendall MP (Labour, Leicester West)
Stephen Metcalfe MP (Conservative, South Basildon and East Thurrock)
Carol Monaghan MP (Scottish National Party, Glasgow North West)
Damien Moore MP (Conservative, Southport)
Neil O’Brien MP (Conservative, Harborough)
Graham Stringer MP (Labour, Blackley and Broughton)
Martin Whitfield MP (Labour, East Lothian)
Powers
The Committee is one of the departmental select committees, the powers of which 
are set out in House of Commons Standing Orders, principally in SO No 152. These 
are available on the internet via www.parliament.uk.
Publication
Committee reports are published on the Committee’s website at 
www.parliament.uk/science and in print by Order of the House.
Evidence relating to this report is published on the relevant inquiry page of the 
Committee’s website.
Committee staff
The current staff of the Committee are: Simon Fiander (Clerk); Yohanna Sallberg 
(Second Clerk); Dr Harry Beeson (Committee Specialist); Martin Smith (Committee 
Specialist); Seb Motala (Committee Specialist); Sonia Draper (Senior Committee 
Assistant); Julie Storey (Committee Assistant); and Sean Kinsey (Media Officer).
Contacts
All correspondence should be addressed to the Clerk of the Science and 
Technology Committee, House of Commons, London SW1A 0AA. The telephone 
number for general inquiries is: 020 7219 2793; the Committee’s e-mail address is: 
scitechcom@parliament.uk.
1 Brexit, science and innovation: Government Response to the Committee’s Second Report 
Fifth Special Report
On 21 March 2018 the Committee published its Second Report of Session 2017–19, Brexit, 
science and innovation [HC 705]. On 26 April 2018 we received the Government’s response 
to the Report, which is appended below.
Appendix: Government response
The Government welcomes the Science and Technology Select Committee’s report 
‘Brexit, Science and Innovation’, and is grateful for the Committee’s positive view on the 
Government’s input to the EU’s consultation on the shape of Framework Programme 9 
(FP9). The Committee’s report highlights key issues that will need to be considered as 
we leave the European Union and continuing to build the broadest and deepest possible 
partnership with the EU on Science and Innovations remains a top priority.
The UK seeks to secure the best possible outcome for the UK research base as we exit the 
European Union, enabling the UK to continue collaborating with our European partners 
through an ambitious science and innovation pact.
As made clear in the UK’s position paper on Framework Programme 9, a continued focus 
on excellence is essential, and the EU and its Member States should facilitate and strengthen 
collaborative working with other countries on shared priorities for mutual benefit. The 
principles of excellence and competitiveness that underpin European collaboration drive 
up the quality of research outputs and contribute to higher skills levels.
The Government’s commitment to underwrite Horizon 2020 funding has provided clarity 
and assurance to UK businesses and universities. This has ensured that researchers can 
confidently bid for funding and continue to participate in, collaborate with partners and 
lead consortia for at least the rest of the programme.
The Government has been consistently clear that the UK is, and will continue to be, a 
place that welcomes talented scientists and researchers from across the globe to work or 
study here. The UK is also committed to continuing to align as closely as possible to the 
EU on clinical trials regulations whilst it remains a member state, as well as ensuring 
streamlined application processes for clinical trials in the UK.
We value the strong collaborative partnerships that we have across the EU in the areas of 
science, research and innovation and recognise the important contribution they make to 
the UK.
Recommendation 1
While the details of the Programme have not yet been agreed, the Government should 
state clearly that it intends to participate unless there is a material unfavourable difference 
between the new Programme and its predecessor, and that the UK is ready to pay a fair 
‘entry fee’ to secure this. If the price is too high, or the focus on excellence is diluted, a change 
in approach might be warranted, but the Government’s explicitly stated assumption must 
be to participate fully. Specifically, the Government should state clearly in its response to this 
Report that it intends to secure Associated Country status for Framework Programme 9.
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Response:
We want to assure the EU and the scientific community of our commitment to ongoing 
collaboration in Science and Innovation.
The UK highly values its participation in EU framework programmes and intends to 
engage fully and constructively in the design of FP9. To that end, we would like to ensure 
Framework Programme 9 remains open to our association. We recognise that such an 
association would necessarily involve an appropriate financial contribution in line with 
other associates and would like to discuss the details.
Overall, our priorities for the programme lie in three primary areas. The first being that the 
programme remains focussed on excellence, EU- added value and openness to the world 
(as outlined in our position paper). Secondly, we want to ensure appropriate financial 
contributions for associated countries. Finally, confirmation that the programme allows 
associated countries a suitable degree of influence, in recognition of the benefits they bring 
to the programme, and in line with their financial contributions.
Recommendation 2
We recommend that the Government ask the Migration Advisory Committee to bring 
forward its conclusions in relation to the immigration arrangements needed to support 
science and innovation and build these into a science and innovation agreement with the EU 
by October 2018 or earlier if possible. We are concerned that if a people-centred science and 
innovation pact is negotiated later it risks being less comprehensive due to other negotiation 
priorities of the wider post-Brexit trade deal. Furthermore, if a pact is not agreed in late 2018 
this will increase risks to retaining and attracting the essential talent that our science and 
innovation sectors need.
Response:
We recognise that science, research and innovation are all vital to the UK’s prosperity, 
security and wellbeing, and are at the heart of our Industrial Strategy – and that access 
to talent after we leave the EU remains a key issue for business and individual migrants.
That is why, in January of this year, we implemented a number of measures that 
demonstrate our commitment to continuing to make the UK a country that welcomes the 
best worldwide talent in the science and research sectors. For example, we have doubled 
the number of Tier 1 Exceptional Talent visas from 1000 to 2000 annually, for top global 
scientists - exceptional researchers - as well as those qualifying in the wider tech, creative 
and arts sectors, and have streamlined the endorsement process to the Tier 1 (Exceptional 
Talent) visa system, greatly reducing time and paperwork for applicants.
The measures also provide for a reduction in the time required to apply for settlement 
(from five years to three) for those qualifying under the Tier 1 Exceptional Talent route. 
To benefit the sector further, we have waived the Resident Labour Market Test (RLMT) 
requirement under Tier 2, our main immigration work route for skilled non-EEA migrants, 
for supernumerary research posts supported by awards and fellowships, so these posts 
don’t need to be first advertised for four weeks.
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We further waived the RLMT for established research teams who are sponsored by UK 
higher education institutions and the Research Councils (now UKRI). We have also 
enabled faster switching between the Tier 4 student route into Tier 2, continuing our 
support of those in the earliest stages of their careers. The sector has been extremely 
positive about the impact of the changes made and these have been warmly received by 
UK Research and Innovation (UKRI) amongst others.
We continue to work closely with the research sector to ensure that our visa arrangements 
for international researchers are closely aligned to the sector’s needs, such as to deliver the 
commitment we made in the 2017 Autumn Budget to expand the number of institutions 
who can sponsor temporary workers under Tier 5, which will make it easier for Research 
Councils and similar organisations to bring researchers to the UK for up to two years.
This will help to underpin the UK’s position as a hub for international collaboration and 
research excellence.
We are carefully considering a range of options for the future immigration system and 
are keen to ensure that decisions on our future immigration arrangements are based 
on evidence. That is why, on 27 July 2017, we commissioned the independent Migration 
Advisory Committee (MAC) to gather evidence on patterns of EU migration and the role 
of migration in the wider economy and how our immigration system should be aligned to 
the modern industrial strategy, ahead of our exit from the EU. We note the contents of the 
MAC’s interim report, published on 27 March, and look forward to the publication of the 
final report in September of this year to allow us to consider fully the recommendations 
as to the future immigration system. We believe that the timescales set out for the MAC 
report are appropriate to meet the scale of the task set and have no plans to ask the MAC 
to expedite their review. The Government will have plenty of time to take account of the 
MAC’s advice when making any final decisions about our future immigration system, 
which will not be implemented until after the end of the Brexit transition period.
Recommendation 3
The Science Minister’s response to us on clinical trials regulation is unsatisfactory. His 
position that “the current regulatory approval legislation will stay in place until such time 
as any changes are needed” ignores the fact that work is needed now to ensure that the UK 
can participate in and lead clinical trials in the future. We recommend that the Government 
revisit this statement in its response to our report.
Response:
As the UK is committed to remain one of the best places in the world for science and 
innovation, it is important that the UK clinical trial’s framework will continue to be 
competitive and effective.
Currently a clinical trial being conducted in multiple EU countries requires individual 
national approvals in each of the countries involved, according to their national laws 
transposed from the Clinical Trials Directive. This will remain the case following the 
implementation of the Clinical Trials Regulation (CTR) as Members States will still 
individually approve clinical trials, albeit through a harmonized application process and 
a single application point.
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Indeed, the UK is already taking steps to implement a more joined up system between 
our national competent authorities on helping establish clinical trials, in advance of the 
EU systems that will be applied under the CTR. Our national system is being designed 
to accept the same application package and to function similarly to the future EU system 
under the CTR, so we will have an efficient and effective approvals system for trials, 
regardless of the Brexit outcome.
Regardless of the outcome of the negotiations, the Government will ensure that after 
the end of the Implementation Period, our national legislation will protect the rights, 
safety, dignity and well-being of research participants in the UK to the same degree as 
research participants in other EU Member States. Our national legislation will reflect 
globally acceptable standards of good clinical practice and will help us to collaborate with 
regulators across the world to share information about patient safety. The Government 
will also continue to support patients and stakeholders with their planning.
We will ensure that UK clinical trials will have the same high standards of transparency 
as trials based in other EU Member States. Whether through access to the EMA portal 
and database, or through an equivalent national database for the UK. The public, industry 
and regulators globally, will have access to the same level of information about UK clinical 
trials as trials registered in EU Member States.
The Government is working to ensure that we continue cooperation with the EU after we 
leave. The Prime Minister has been clear that this involves us wanting to make sure our 
regulators continue to work together, as they already do with regulators internationally. 
Both the Secretary of State for Health and Social Care and Secretary of State for Business, 
Energy and Industrial Strategy could not have been clearer in their letter to the Financial 
Times in July 2017: “In regulation of medicines as we leave the EU, the UK is fully 
committed to continuing the close working relationship with our European partners”.
Recommendation 4
Given the significance of science and innovation to the UK economy, reaching an agreement 
on this should now be as important to the Government as the question of security. It must be 
stripped out from the wider trade negotiations for focused attention, rather than become a 
knock-on consequence of other negotiations or traded against other aspects of a post-Brexit 
deal. We do not accept that ‘nothing is agreed until everything is agreed’ in this context. We 
recommend that the Government make drafting and negotiating a science and innovation 
agreement an urgent priority. Our report sets out the key issues that such an agreement 
should cover.
Response:
The UK has consistently expressed its desire for continued collaboration on S&I with the 
EU. This position was reinforced by the Prime Minister on 2 March 2018 who reiterated 
that the UK is committed to establishing a ‘far-reaching science and innovation pact 
with the EU, facilitating the exchange of ideas and researchers.’ We would like to discuss 
possible options as soon as possible.
